JG26 可减轻 ADAM17 金属蛋白酶介导的 ACE2 受体处理和体外 SARS-CoV-2 感染

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY Pharmacological Reports Pub Date : 2024-09-18 DOI:10.1007/s43440-024-00650-0

Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, Marco Macchia, Armando Rossello, Daria Bortolotti, Elisa Nuti

{"title":"JG26 可减轻 ADAM17 金属蛋白酶介导的 ACE2 受体处理和体外 SARS-CoV-2 感染","authors":"Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, Marco Macchia, Armando Rossello, Daria Bortolotti, Elisa Nuti","doi":"10.1007/s43440-024-00650-0","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>ADAM17 is a metalloprotease implicated in the proteolysis of angiotensin-converting enzyme 2 (ACE2), known to play a critical role in the entry and spread of SARS-CoV-2. In this context, ADAM17 results as a potential novel target for controlling SARS-CoV-2 infection.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this study, we investigated the impact on ACE2 surface expression and the antiviral efficacy against SARS-CoV-2 infection of the selective ADAM17 inhibitor JG26 and its dimeric (compound <b>1</b>) and glycoconjugate (compound <b>2</b>) derivatives using Calu-3 human lung cells.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>None of the compounds exhibited cytotoxic effects on Calu-3 cells up to a concentration of 25 µM. Treatment with JG26 resulted in partial inhibition of both ACE2 receptor shedding and SARS-CoV-2 infection, followed by compound <b>1</b>.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>JG26, an ADAM17 inhibitor, demonstrated promising antiviral activity against SARS-CoV-2 infection, likely attributed to reduced sACE2 availability, thus limiting viral dissemination.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":"12 1","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro\",\"authors\":\"Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, Marco Macchia, Armando Rossello, Daria Bortolotti, Elisa Nuti\",\"doi\":\"10.1007/s43440-024-00650-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background</h3><p>ADAM17 is a metalloprotease implicated in the proteolysis of angiotensin-converting enzyme 2 (ACE2), known to play a critical role in the entry and spread of SARS-CoV-2. In this context, ADAM17 results as a potential novel target for controlling SARS-CoV-2 infection.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>In this study, we investigated the impact on ACE2 surface expression and the antiviral efficacy against SARS-CoV-2 infection of the selective ADAM17 inhibitor JG26 and its dimeric (compound <b>1</b>) and glycoconjugate (compound <b>2</b>) derivatives using Calu-3 human lung cells.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>None of the compounds exhibited cytotoxic effects on Calu-3 cells up to a concentration of 25 µM. Treatment with JG26 resulted in partial inhibition of both ACE2 receptor shedding and SARS-CoV-2 infection, followed by compound <b>1</b>.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>JG26, an ADAM17 inhibitor, demonstrated promising antiviral activity against SARS-CoV-2 infection, likely attributed to reduced sACE2 availability, thus limiting viral dissemination.</p>\",\"PeriodicalId\":19947,\"journal\":{\"name\":\"Pharmacological Reports\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacological Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s43440-024-00650-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43440-024-00650-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

背景ADAM17是一种金属蛋白酶，与血管紧张素转换酶2（ACE2）的蛋白水解有关，已知ACE2在SARS-CoV-2的进入和传播中起着关键作用。方法在这项研究中，我们使用 Calu-3 人肺部细胞研究了选择性 ADAM17 抑制剂 JG26 及其二聚体（化合物 1）和糖结合体（化合物 2）衍生物对 ACE2 表面表达的影响以及对 SARS-CoV-2 感染的抗病毒效果。结论JG26 是一种 ADAM17 抑制剂，对 SARS-CoV-2 感染具有良好的抗病毒活性，这可能是由于 sACE2 的可用性降低，从而限制了病毒的传播。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro

Background

ADAM17 is a metalloprotease implicated in the proteolysis of angiotensin-converting enzyme 2 (ACE2), known to play a critical role in the entry and spread of SARS-CoV-2. In this context, ADAM17 results as a potential novel target for controlling SARS-CoV-2 infection.

Methods

In this study, we investigated the impact on ACE2 surface expression and the antiviral efficacy against SARS-CoV-2 infection of the selective ADAM17 inhibitor JG26 and its dimeric (compound 1) and glycoconjugate (compound 2) derivatives using Calu-3 human lung cells.

Results

None of the compounds exhibited cytotoxic effects on Calu-3 cells up to a concentration of 25 µM. Treatment with JG26 resulted in partial inhibition of both ACE2 receptor shedding and SARS-CoV-2 infection, followed by compound 1.

Conclusion

JG26, an ADAM17 inhibitor, demonstrated promising antiviral activity against SARS-CoV-2 infection, likely attributed to reduced sACE2 availability, thus limiting viral dissemination.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacological Reports 医学-药学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures. Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology. Studies of plant extracts are not suitable for Pharmacological Reports.